

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
September 28, 2016
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, September 28, 2016.

2. Welcome

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Joni Bollinger, MD
Philip Mubarak, MD
Divya Ahuja, MD

Tan Platt, MD
Edward Behling, MD
Gregory Browning, MD

Cheryl Hartvigsen, R.Ph.

SC DHHS Staff:

Bryan Amick, PharmD, MBA
Jim Bradford, MD
Janet Giles
Constance Holloway, JD

Magellan Medicaid Admin:

Lisa Correll, PharmD
Lori Ash

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, May 18, 2016

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class
Novartis Pharmaceuticals	Sharon Hernandez, PharmD†	ARNI
Purdue Pharma	Brian Howell, PharmD, MBA	Analgesics, Long Acting Narcotics
Abbvie	Andrea Hume, MD†	Hepatitis C
Gilead Sciences	Michele Puyear, PharmD†	Hepatitis C
Merck	Roderick Teat, PharmD†	Hepatitis C

† Speakers gave their time back to the Committee.

C. Drug Classes for Review

Lisa Correll led the discussion for the following drug classes:

Class for Review

ARNI (ARB/Neprilysin Inhibitor Combo) (CHF)

Classes for Re-Review

Analgesics, Long Acting Narcotics

Anti-Migraine Triptans (Serotonin Agonists)

Hepatitis C

The chart below represents the recommendations from the P & T Committee:

ARNI: ARB/NEPRILYSIN INHIBITOR COMBO	
Preferred	Non-Preferred
Entresto™	

ANALGESICS, LONG ACTING NARCOTICS	
Preferred	Non-Preferred
Butrans®	Avinza®
Embeda®	Belbuca™
Fentanyl	ConZip™
Morphine Sulfate ER/SA	Duragesic®
	Exalgo®
	Hysingla® ER
	Kadian®
	MS Contin®
	Nucynta®
	Oramorph®
	Opana®
	OxyContin®
	Ultram ER®

ANALGESICS, LONG ACTING NARCOTICS (continued)	
Preferred	Non-Preferred
	Xtampza™ ER Zohydro® ER

ANTI MIGRAINE – TRIPTANS (SEROTONIN INHIBITORS)	
Preferred	Non-Preferred
Sumatriptan Tab/Injection/Spray Relpax® Rizatriptan tab/odt	Alsuma® Amerge® Axert® Frova® Imitrex® Maxalt® Migranow Onzetra™ Xsail™ Sumavel® Treximet® Zecuity® Zembrace™ SymTouch™ Zomig®

HEPATITIS C	
Preferred	Non-Preferred
Epclusa® Harvoni® Viekira/XR™ Technivie™ Zepatier™	Daklinza™ Olysio® Sovaldi®

5. **Old Business**

None

6. **New Business**

Bryan advised the group that HCV coverage will expand beginning October 1, 2016. SC DHHS will expand coverage to include F2, they will continue allowance for special circumstances and further expansion is expected in 2017.

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

Class for Review

ARNI (ARB/Neprilysin Inhibitor Combo) (CHF)

Classes for Re-Review

Analgesics, Long Acting Narcotics

Anti-Migraine Triptans (Serotonin Agonists)

Hepatitis C

8. Closing Comments

The next meeting will be held on Wednesday, November 2, 2016, at 4:00 p.m.

9. Adjournment

The meeting adjourned at 5:26 p.m.